AnaptysBio (ANAB) PT Lowered to $52 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
AnaptysBio (ANAB) PT Lowered to $45 at Leerink Partners
November 6, 2024 5:58 AM ESTLeerink Partners analyst David Risinger lowered the price target on AnaptysBio (NASDAQ: ANAB) to $45.00 (from $47.00) while maintaining a Outperform rating.
The analyst comments " Bottom Line: ANAB reported 3Q results and stated that there have been no blinded safety issues to date with either its BTLA... More
AnaptysBio, Inc. (ANAB) Tops Q3 EPS by 56c
November 5, 2024 4:58 PM ESTAnaptysBio, Inc. (NASDAQ: ANAB) reported Q3 EPS of ($1.14), $0.56 better than the analyst estimate of ($1.70). Revenue for the quarter came in at $30.02 million versus the consensus estimate of $6.92 million.
For earnings history and earnings-related data on AnaptysBio, Inc. (ANAB) click here.
... MoreAnaptysbio (ANAB) Files $500M Mixed Shelf
November 5, 2024 4:30 PM ESTAnaptysbio (NASDAQ: ANAB) has filed $500,000,000 mixed shelf of:
Common Stock, Preferred Stock, Debt Securities, Warrants, Subscription Rights and Units
